NASDAQ$AMLX
Amylyx Pharmaceuticals Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Amylyx reported positive net income and revenue growth, driven by increased sales of RELYVRIO and ALBRIOZA.
Amylyx Pharmaceuticals reported Q4 2023 financial results, highlighted by $108.4 million in net product revenue and a net income of $4.7 million. The company's full-year revenue reached $380.8 million, with a net income of $49.3 million. Amylyx is progressing its clinical trials and expanding the commercialization of its ALS treatments.
- Net product revenue for Q4 2023 was $108.4 million.
- Net income for Q4 2023 was $4.7 million.
- Cash, cash equivalents, and short-term investments totaled $371.4 million as of December 31, 2023.
- Amylyx is advancing clinical trials for AMX0035 in PSP and Wolfram syndrome.
Headline financials
Revenue & EPS history
Amylyx · Revenue · Quarterly
$108M
Forward guidance
Amylyx anticipates sharing topline data from its Phase 3 PHOENIX trial during or before the second quarter of 2024 and continues to progress its R&D programs.
Tailwinds
- Topline data from Phase 3 PHOENIX trial expected during or before Q2 2024.
- Advancing AMX0035 in Progressive Supranuclear Palsy (PSP) through Phase 3 ORION trial.
- Data from Phase 2 HELIOS trial in Wolfram syndrome expected in 2024.
- AMX0114, an antisense oligonucleotide, is entering the clinic.
- Working on a new taste-masked formulation of RELYVRIO that may allow for new intellectual property.
Headwinds
- The Phase 3 ORION trial topline results are not anticipated until 2025 or 2026.
- Potential risks associated with disorders that interfere with bile acid circulation.
- Potential risks associated with high sodium intake from RELYVRIO.
- Uncertainties regarding the success, cost, and timing of program development activities.
- Dependence on successful commercialization of RELYVRIO and ALBRIOZA.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q4 2023
+0.3%
Avg return
Earnings day
+2.5%
Avg return
5 days after
+7.4%
Avg return
30 days after
44%
8 / 18 earnings
Positive
+23.4%
Q4 2021
Best reaction
-30.7%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -7.6% | -9.5% | -2.3% | |
| Q3 2025 | -5.9% | -4.2% | +7.3% | |
| Q1 2025 | -6.0% | -7.8% | +9.4% | |
| Q4 2024 | +0.3% | +29.0% | +17.0% | |
| Q3 2024 | +7.7% | +0.3% | -17.4% | |
| Q2 2024 | +1.1% | +5.9% | +26.1% | |
| Q1 2024 | -8.8% | -3.1% | -8.3% | |
| Q4 2023 | +15.3% | +24.1% | -82.1% | |
| Q3 2023 | -30.7% | -30.4% | -22.2% | |
| Q2 2023 | +0.5% | -2.3% | -4.5% | |
| Q1 2023 | -4.4% | -6.1% | -11.9% | |
| Q4 2022 | +11.2% | -1.2% | -3.9% | |
| Q3 2022 | -1.8% | +2.4% | +3.0% | |
| Q3 2021 | -1.8% | +2.4% | +3.0% | |
| Q2 2021 | -5.5% | -5.7% | +12.7% | |
| Q2 2022 | -5.5% | -5.7% | +12.7% | |
| Q4 2021 | +23.4% | +28.2% | +97.5% | |
| Q1 2022 | +23.4% | +28.2% | +97.5% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro